MasterSeal M 689 — new waterproofing solutions for the chemical and pharmaceutical industries
![](/46/pdcnewsitem/03/78/22/BASF.png)
High elasticity and crack bridging ensure durability of the membrane even in contact with unstable substrates.
In chemical and pharmaceutical industries, environmentally hazardous chemicals and liquids are frequently an indispensable part of the production process. They require special measures for safe storage and handling. In addition, to prevent pollution of soil and water, secondary containment is required by national laws to control eventual liquid spillages to protect the environment. Especially for this purpose Master Builders Solutions by BASF offers waterproofing solutions also for complex industrial structures.
Secondary containment is theoretically only used when accidental spillage takes place but, in practice, minor quantities of chemicals often escape from valves, connections, joints, etc. These chemicals damage concrete structures and floors and can penetrate into soil causing, in some cases, severe contaminations. When waterproofing capabilities have to be complemented by resistance to chemicals solved in water, special resin based membranes are the best choice as they combine continuous, seamless and crack-bridging waterproofing properties with high chemical resistance.
MasterSeal M 689 combines this high chemical resistance to a wide range of chemicals with an outstanding elasticity and toughness ensuring long term durability of the membrane, even exposed to the most demanding situations. In addition, MasterSeal M 689 has high mechanical resistance, so it can even be used in storage areas with regular traffic. With high elastic and chemical resistance waterproofing membranes such as MasterSeal M 689, secondary containment facilities, basins, pipeline bridges or trafficked impounding basins, are long term protected and any leakage stopped before it reaches soil or groundwater.
MasterSeal M 689 shows high crack bridging capacities, both static (Class A5 according EN 1504 part 2) and dynamic (Class B4.2 according EN 1504 part 2) even at temperatures below zero. In addition, long-term chemical resistance to the exposure to a wide range of different agents even under pressure is proven and documented (Class III according EN 13529). That is why MasterSeal M 689 also fulfils the requirements of the German Wasser-Haushalts-Gesetz (WHG) for the use in so-called LAU (German: Lagern/ Abfüllen/ Umschlagen; English: Storage/ Filling/ Handling) areas in industrial environments.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance